IRIS
Cao, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.633
AS - Asia 2.194
EU - Europa 793
SA - Sud America 371
Continente sconosciuto - Info sul continente non disponibili 112
AF - Africa 50
OC - Oceania 5
Totale 7.158
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.511
SG - Singapore 1.239
CN - Cina 508
BR - Brasile 308
VN - Vietnam 196
DE - Germania 195
FI - Finlandia 149
IT - Italia 141
IE - Irlanda 80
CA - Canada 62
GB - Regno Unito 55
IN - India 50
FR - Francia 48
HK - Hong Kong 45
SE - Svezia 41
BD - Bangladesh 27
MX - Messico 26
IQ - Iraq 23
AR - Argentina 22
RU - Federazione Russa 16
PL - Polonia 14
ES - Italia 13
JP - Giappone 12
ZA - Sudafrica 12
CO - Colombia 11
TR - Turchia 11
EG - Egitto 10
ID - Indonesia 10
NG - Nigeria 10
NL - Olanda 10
PK - Pakistan 10
CR - Costa Rica 9
EC - Ecuador 7
MA - Marocco 7
MY - Malesia 7
PY - Paraguay 7
UA - Ucraina 7
VE - Venezuela 7
NP - Nepal 6
JM - Giamaica 5
KZ - Kazakistan 5
SA - Arabia Saudita 5
TH - Thailandia 5
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
BE - Belgio 4
JO - Giordania 4
PH - Filippine 4
PR - Porto Rico 4
UZ - Uzbekistan 4
BB - Barbados 3
CL - Cile 3
CU - Cuba 3
EE - Estonia 3
IL - Israele 3
KE - Kenya 3
PE - Perù 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
AF - Afghanistan, Repubblica islamica di 2
BO - Bolivia 2
DZ - Algeria 2
GT - Guatemala 2
LB - Libano 2
LT - Lituania 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AG - Antigua e Barbuda 1
AT - Austria 1
BH - Bahrain 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GR - Grecia 1
IM - Isola di Man 1
IR - Iran 1
KR - Corea 1
KW - Kuwait 1
LU - Lussemburgo 1
MN - Mongolia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TG - Togo 1
TW - Taiwan 1
UG - Uganda 1
UY - Uruguay 1
Totale 7.046
Salva come PNG Salva come JPEG
Città #
Dallas 588
Singapore 525
San Jose 432
Ashburn 345
The Dalles 209
Shanghai 180
Beijing 155
Helsinki 148
Council Bluffs 129
Falkenstein 128
Boardman 104
New York 102
Chandler 90
Dublin 79
Ho Chi Minh City 68
Los Angeles 63
Santa Clara 63
Milan 51
Wilmington 49
Hanoi 45
Hong Kong 43
São Paulo 29
North Bergen 26
Chicago 25
Phoenix 25
San Mateo 24
Brooklyn 22
Rome 22
Pune 19
Seattle 19
Buffalo 18
Ann Arbor 17
Princeton 15
Assago 12
Houston 12
Mexico City 12
Philadelphia 12
Stockholm 12
Lawrence 11
Warsaw 11
Benin City 10
Montreal 10
Munich 10
Columbus 9
Leawood 9
London 9
Paris 9
Rio de Janeiro 9
San Francisco 9
Toronto 9
Curitiba 8
Da Nang 8
Lauterbourg 8
Naples 8
Orem 8
Porto Alegre 8
San Diego 8
Baghdad 7
Denver 7
Long Beach 7
San José 7
Tokyo 7
Amsterdam 6
Atlanta 6
Brasília 6
Charlotte 6
Dhaka 6
Fairfield 6
Frankfurt am Main 6
Haiphong 6
Abbiategrasso 5
Asunción 5
Belo Horizonte 5
Biên Hòa 5
Boston 5
Düsseldorf 5
Johannesburg 5
New Delhi 5
Newark 5
Queens 5
Reston 5
Richmond 5
Santo André 5
Woodbridge 5
Birmingham 4
Brussels 4
Campinas 4
Changsha 4
Detroit 4
Greenville 4
Kingston 4
Manchester 4
Miami 4
Mumbai 4
Orlando 4
San Antonio 4
San Juan 4
Shijiazhuang 4
Tashkent 4
Thái Bình 4
Totale 4.305
Salva come PNG Salva come JPEG
Nome #
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program 655
Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: an updated systematic review and meta-analysis 166
Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. 157
On the Modeling of Patient-Specific Transcatheter Aortic Valve Replacement: A Fluid–Structure Interaction Approach 104
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent 92
Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy 92
The synergy stent in high-bleeding risk patients: why design matters 92
Clinical Outcomes and Revascularization Strategies in Patients With Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the Assigned Treatment Modality 91
Coronary Artery Disease Severity and Aortic Stenosis: Clinical Outcomes According to SYNTAX-Score in Patients Undergoing Transcatheter Aortic Valve Implantation 91
Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents 89
A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry 78
Contrast-induced acute kidney injury 76
Coronary Revascularisation in Transcatheter Aortic Valve Implantation Candidates: Why, Who, When? 76
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR 75
Short Versus Long Duration of DAPT After DES Implantation: A Meta-Analysis. 75
Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents 73
Aspirin-free strategies: a framework to reassess the role of dual antiplatelet therapy after percutaneous coronary intervention 72
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management 72
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents 72
Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials 71
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies 70
Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial 70
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI 69
Depression and ischemic heart disease 69
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation 68
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey 68
Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI 68
Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry) 67
Platelets and the Atherosclerotic Process: An Overview of New Markers of Platelet Activation and Reactivity, and Their Implications in Primary and Secondary Prevention 67
Revascularization in patients with valvular heart disease 67
Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies 67
Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis 65
Residual SYNTAX Score and One-Year Outcome in Elderly Patients With Acute Coronary Syndrome 65
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis 64
Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench-to-bedside 64
Assessing the risk of acute kidney injury after primary PCI: The simpler the sooner the better 64
A sex paradox in clinical outcomes following complex percutaneous coronary intervention 64
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD 64
Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris 63
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index 63
PROGNOSTIC VALUE OF HIGH-SENSITIVITY C-REATIVE PROTEIN AMONG CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION 63
Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention 62
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials 62
Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis 62
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review 60
Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVO-3 randomized trial 60
Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI 60
Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft 59
Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry 59
Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Complex PCI: A Collaborative Systematic Review and Meta-Analysis 58
Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding 58
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients 58
ARC-HBR criteria and TAVR: not all high bleeding risk patients look alike 57
Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI 57
Pericardial Effusion Provoking Atrial Fibrillation After Cardiac Surgery: JACC Review Topic of the Week 57
Recent Advances in Antiplatelet Therapy in Complex Percutaneous Coronary Intervention 57
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD 57
Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry 56
One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease 56
The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent 56
Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial 56
Clopidogrel Monotherapy After 1-Month DAPT in Diabetic Patients Undergoing PCI: Is Less Always More? 56
Predictors of antiplatelet cessation in a real-world patient population undergoing non-cardiac surgery after PCI 55
Types of myocardial injury and mid-term outcomes in patients with COVID-19 54
Clinical and procedural outcomes of percutaneous coronary intervention for de novo lesions involving the ostial left circumflex coronary artery 54
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy 54
Management of Adults With Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review 53
New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention 53
Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry 53
Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease: JACC Focus Seminar 3/7 53
Vitamin D and Cardiovascular Diseases: From Physiology to Pathophysiology and Outcomes 53
Treating Inflammation Prior to Percutaneous Coronary Intervention: Does the Heart Care? 52
The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry 52
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study 52
Prevalence and prognostic impact of hsCRP elevation are age-dependent in women but not in men undergoing percutaneous coronary intervention 51
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 51
Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry 51
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI 51
Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial 49
Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis 48
From surgical clamping to endovascular flow arrest/reversal: the concept behind the system 47
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention 47
Ticagrelor Monotherapy After Coronary Stenting: Is the GLASS Half Full or Half Empty? 47
Minding the Microcirculation: Is it Worth the Effort? 46
Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI 46
Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria 45
Ticagrelor in Patients With Cancer: 2 Birds With 1 Stone 44
Rethinking the Role of Impaired Renal Function in Multivessel PCI or CABG 44
Impact of sex on long-term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes 43
Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design 43
Stick to the guidelines or clinical judgment: A toss up? 43
Sodium Bicarbonate, Contrast-Associated Acute Kidney Injury, and Long-Term Outcomes: The End of an Era? 42
Periprocedural anticoagulation in non-ST-segment elevation acute coronary syndrome: time to reassess? 42
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis 42
Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry 41
Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction 41
Subjective angina or myocardial ischaemia to justify PCI? Never mistake the finger for the moon 41
Impact of Bleeding Risk and Inflammation on Cardiovascular Outcomes After Percutaneous Coronary Intervention 41
GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes 40
Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease 40
Totale 6.785
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202252 0 0 0 13 2 1 0 6 5 2 15 8
2022/2023487 21 5 13 43 33 30 77 27 92 99 38 9
2023/2024686 69 51 152 37 12 84 51 14 23 37 81 75
2024/20251.095 22 3 17 11 19 139 70 83 198 282 137 114
2025/20263.564 407 294 539 241 127 150 886 219 164 215 112 210
2026/20271.168 105 245 607 211 0 0 0 0 0 0 0 0
Totale 7.158